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Abstract
Thirteen homologous proteins comprise the long-chain acyl-CoA synthetase (ACSL), fatty acid
transport protein (FATP), and bubblegum (ACSBG) subfamilies that activate long-chain and very-
long-chain fatty acids to form acyl-CoAs. Gain- and loss-of-function studies show marked
differences in the ability of these enzymes to channel fatty acids into different pathways of complex
lipid synthesis. Further, the ability of the ACSLs and FATPs to enhance cellular FA uptake does not
always require these proteins to be present on the plasma membrane; instead, FA uptake can be
increased by enhancing its conversion to acyl-CoA and its metabolism in downstream pathways.
Since altered fatty acid metabolism is a hallmark of numerous metabolic diseases and pathological
conditions, the ACSL, FATP and ACSBG isoforms are likely to play important roles in disease
etiology.
A family of acyl-CoA synthetases activates intracellular long-chain fatty acids
Before a fatty acid (FA) from an exogenous or endogenous source can enter any metabolic
pathway with the exception of eicosanoid metabolism, it must first be activated to form an
acyl-CoA. This activation step is catalyzed by acyl-CoA synthetase (ACS) via a two-step
reaction: 1) the formation of an intermediate fatty acyl-AMP with the release of pyrophosphate,
and 2) the formation of a fatty acyl-CoA with the release of AMP.
The ACS family is comprised of at least 25 members [1]. Although overlap exists, ACS family
members are broadly classified by their substrate specificities for FAs of varying chain length.
This review will focus on the three subfamilies of ACS enzymes that activate long-chain and/
or very-long-chain saturated and unsaturated FAs, long-chain ACSs (ACSL), very-long-chain
ACSs (FATP), and bubblegum (ACSBG) isoforms [2].
The ACSL, FATP and ACSBG families include multiple isoforms, each encoded by a separate
gene (Tables 1, 2). Additionally, splice variants of ACSL isoforms have been identified in both
humans and rodents [3]. ACS enzymes share significant amino acid sequence similarity,
particularly in two highly conserved regions, a putative ATP-AMP signature motif for ATP
binding and a motif for FA binding [4]. Despite these similarities, purified ACSL and FATP
isoforms and their splice variants show distinct enzyme kinetics, differences in sensitivity to
inhibitors (Table 1,2) and differences in their substrate preferences. For example, ACSL4 has
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a marked preference for C20:4 [5], whereas ACSL1 prefers saturated and monounsaturated
FA that are 16–18 carbons in length [6]. Very-long-chain ACS isoforms, also designated as
FATP (FA transport proteins), generally prefer 16–18 carbon FA but can also activate FA as
long as 26 carbons [7,8]. It should be noted that FAs may not only be the sole substrate for
some isoforms. For example, FATP5 preferentially activates bile acids and FATP2 activates
both long-chain FA and 3α, 7α, 12α-trihydroxy-5β-cholestanoate [9]. The ACSBG isoforms
prefer long-chain FA [10,11].
The intracellular locations of the ACSL and FATP isoforms differ depending upon the cell
type (Table 1). Not only can several ACSL isoforms be present in different subcellular locations
within a single cell, but a single ACSL isoform may vary in its subcellular location. For
example, ACSL1 has been reported to be located on the plasma membrane [12] and in GLUT4
vesicles [13] in adipocytes, and on the ER in hepatocytes [14] and mitochondria in epithelial
cells [15]. Cell-specific differences in location could arise by differential splicing or protein-
protein interactions, both of which may contribute to tissue-specific functions. Such functions
include facilitating FA uptake into cells, channeling FAs towards specific synthetic and
degradative pathways, and regulating the use of FAs and acyl-CoAs as ligands for transcription
factors and as modifiers of cellular physiology.
Role of acyl-CoA synthetases in modulating FA uptake
The FATP family was discovered in 1994 when Schaffer and Lodish searched for adipocyte
proteins that would increase cellular uptake of the fluorescent FA analog Bodipy-C12 [16].
They cloned two proteins–one was the previously cloned ACSL1 [6], and they named the other
FATP (subsequently FATP1). An additional 5 FATP isoforms have since been cloned, and
considerable discussion has taken place regarding whether the FATP family members transport
FA directly or, instead, indirectly facilitate FA transport.
Both in vitro and in vivo studies in a variety of cell types and tissues have shown that
manipulating the expression of FATP1 affects FA uptake [17–19]. Interestingly, insulin causes
FATP1 and FATP4 to translocate from the ER to the plasma membrane, a process that could
enable insulin to enhance FA uptake [20]. The location of FATP5 on the basal plasma
membrane of hepatocytes [21] and FATP6 on the plasma membrane of monkey cardiac
myocytes [22] suggest that a plasma membrane location is required to mediate FA uptake,
since hepatocytes from mice lacking FATP5 have 50% lower rates of FA uptake and
overexpressing FATP6 in HEK293 cells enhances FA uptake [21,22].
However, in some instances FA uptake appears to depend more on inherent ACS activity than
on a plasma membrane location, and some members of the FATP and ACSL families increase
FA uptake despite their location on internal cell membranes. For example, overexpressing
ACSL and FATP isoforms increases FA uptake despite the fact that ACSL1 [15,23], ACSL4
[24], ACSL5 [25], and FATP4 [15] are located only on intracellular organelles in the cells
examined. (FATP4 is present on the apical side of enterocytes but it was not located to a specific
membrane [26]). Like the ACSL family members, most FATP isoforms have either been
directly or indirectly shown to possess ACS activity. Purified FATP1 and FATP4 activate a
wide range of FAs and show no preference for very-long-chain FAs [7,27]. Additionally, when
overexpressed in a genetically modified yeast strain with low ACS activity, all FATPs with
the exception of FATP5 are able to increase ACS activity using different long-chain and very-
long-chain substrates [28]. The same study shows that rates of FA uptake and ACS activity
are often dissociated. Yet, others show that ACS activity is required for FATP-mediated FA
uptake, so that when FATP1 contains a mutation that abolishes ACS activity, overexpression
severely suppresses FA uptake [29]. Similarly, overexpressing normal FATP4 enhances FA
uptake in COS cells, but overexpressing a FATP4 mutant that lacks ACS activity abolishes
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these effects [15]. Clearly, the role of ACS activity of ACSL and FATP isoforms in facilitating
FA transport needs further evaluation.
Because FAs must first be converted to acyl-CoAs before they enter most metabolic pathways,
their activation by ACSLs and FATPs traps them within the cell as acyl-CoAs, and thereby
diminishes intracellular FA pools so that less FA is available for efflux [30]. Thus, intracellular
acyl-CoA metabolism may enhance FA influx regardless of the location of the ACSL or FATP
protein.
Role of acyl-CoA synthetases in FA channeling
The existence of 13 ACSL, FATP and ACSBG isoforms that all activate long-chain FA has
suggested that each has an independent role in channeling FA within cells. Unique roles for
ACS isoforms were first identified in studies of Saccharomyces cerevisiae mutants that lacked
the ACS isoforms Faa1 and Faa4, and were unable to use exogenously provided fatty acids
[31]. Similarly, complementation studies of ACS-deficient E. coli showed that each of the 5
rat ACSL isoforms differs in its ability to channel FA into specific pathways like phospholipid
synthesis and β-oxidation [32]. The ACSL and FATP isoforms also differ in their ability to
complement FA uptake and activation in mutated yeast strains that lack ACS activity [28,33].
In cultured mammalian cells, gain-of-function and loss-of-function studies also strongly
suggest that the different ACSL isoforms channel FA into specific metabolic pathways,
consistent with differences in their subcellular locations and substrate preferences. In rat
hepatocytes and human fibroblasts, for example, triacsin C, a competitive inhibitor of ACSL1,
ACSL3, and ACSL4 [34,35], preferentially decreases [1-14C]oleic acid incorporation into
TAG relative to other glycerolipids and oxidation products [36,37]. These indirect studies
suggested that ACSLs direct the metabolic fate of FAs, but did not identify unique roles for
individual ACSL isoforms.
Overexpression studies in mammalian cells have shown the effects of specific ACSL isoforms
more directly. Adenovirus-mediated overexpression of ACSL5, which doubles total ACS
activity in McArdle-RH7777 rat hepatoma cells, partitions oleic acid almost exclusively into
intracellular TAG without increasing the amount of TAG secreted into the medium [25].
Because overexpressing ACSL5 does not increase the incorporation of [14C]acetic acid into
any lipid class, it appears that ACSL5 uses only exogenous FA and does not activate FA
synthesized de novo within the cell. Overexpressing ACSL1 in NIH-3T3 fibroblasts or PC12
neurons, also increases oleic acid incorporation into TAG [38,39], and in ACSL1 heart-specific
transgenic mice, heart TAG content increases approximately 12-fold and the choline
glycerophospholipid content increases 50% [17], again suggesting an anabolic role for ACSL,
although ACS activity itself was not measured in these hearts. In contrast to its role in TAG
synthesis, overexpressing ACSL1 in rat primary hepatocytes resulted in a 3.7-fold increase in
ACS activity but did not enhance incorporation of oleic acid into TAG [14]; instead, ACSL1
increased oleate incorporation into phospholipid and diacylglycerol while decreasing
incorporation into cholesterol esters. Pulse-chase experiments further revealed that
overexpressed ACSL1 decreased the turnover of intracellular TAG and phospholipids, possibly
through altering the reacylation of lysophospholipids. Unlike ACSL5, overexpressed ACSL1
increases the incorporation of de novo synthesized FA into glycerolipids [14]. In somewhat
contrasting experiments in HepG2 cells, adenovirus-mediated overexpression of ACSL1
resulted in a 20-fold increase in ACS activity, increases in cell acyl-CoA content, and enhanced
oleic acid partitioning into cellular TAG [40]. However in this study, the lack of carnitine in
the medium may have limited CPT-1 activity and FA β-oxidation, while the marked increase
in ACS activity may have overwhelmed other pathways. Adenoviral-mediated overexpression
of ACSL1 in rodent liver in vivo also increased hepatic TAG, but did not affect FA clearance
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from the blood; cholesterol and phospholipid metabolism were not measured [40]. Taken as a
whole, these overexpression studies suggest that, not only do ACSL1 and ACSL5 channel FA
towards different lipid pathways, but that the direction of channeling may vary in different cell
types. A caveat to this interpretation is that in several of the studies cited above, overexpression
was ascertained only by changes in mRNA without measuring ACS activity directly. A very
large increase in activity could potentially give results that are not relevant to the physiological
function.
Similar to these ACSL overexpression studies, altering the expression of FATP isoforms also
affects FA channeling. For example, overexpressing FATP1 in HEK293 cells alters
partitioning of both exogenously added oleic acid and FA synthesized de novo from acetate
into cellular lipids and increases cellular TAG content while decreasing cholesterol and
sphingomyelin content [41]. In skeletal muscle, adenovirus-mediated overexpression of
FATP1 increases the partitioning of oleate or palmitate into TAG and away from β-oxidation
[18], and overexpression in mouse heart increases FA uptake and TAG content and causes a
lipotoxic cardiomyopathy [42]. Conversely, in muscle from FATP1 null mice fed a high fat
diet, the content of TAG, DAG and acyl-CoA is lower than in wildtype controls (Table 3)
[19]. Knockdown of FATP1 in 3T3-L1 adipocytes reduces FA uptake without changes in
lipolysis, but knockdown of FATP4 does the reverse; it does not affect FA influx, but instead,
increases basal lipolysis [43]. In isolated enterocytes, antisense knockdown of FATP4
diminishes the uptake of oleate 50% [26]. Like the ACSL isoforms, these differences in FA
metabolism suggest the possibility that interactions with downstream enzymes may mediate
the fates of acyl-CoAs synthesized by FATP1 and FATP4. To date, however, no studies have
examined such potential interactions. The ACSBG isoforms have not been studied with respect
to FA uptake into cells.
The different substrate preferences of the individual ACSL and FATP isoforms suggest that
altering the activity of a single isoform might change the FA composition of intracellular
glycerolipids. For example, ACSL6 preferentially activates very-long-chain polyunsaturated
FAs, and when ACSL6 is overexpressed in PC12 neurons, it enhances the uptake and
metabolism of docosahexaenoic acid relative to oleic acid [44]. In the several mouse models
that lack FATP4 (Table 3), mice are variably characterized by altered epidermal FA
composition accompanied by a neonatally lethal restrictive dermopathy [45], altered skin
development, impaired hair growth and abnormal lipid metabolism [46], and early embryonic
lethality [47]. The decreased amount of very-long-chain FAs in tissues from FATP4 knockouts
supports data from ACS activity assays showing that FATP4 prefers very-long-chain FAs over
long chain FAs [45]. Supporting this interpretation are data from fibroblasts from FATP4 null
mice in which the rate of 24:0 degradation and incorporation into phospholipids, TAG and
cholesterol esters were diminished [1]. In contrast, compared to wild type controls, livers from
FATP5 null mice contain 60% less TAG, a greater decrease in saturated and polyunsaturated
FAs in TAG relative to monounsaturated FA, and 37% lower unesterified FA [21]. Although
no studies have tested whether the different ACSL and FATP isoforms alter the FA composition
of phospholipids in specific cellular organelles, the FA preferences of these enzymes suggest
that they could mediate the composition of distinct lipid pools.
Differential regulation of acyl-CoA synthetases
Specific functional roles for individual ACSL isoforms are suggested by their tissue-specific
responses to nutritional changes and to unique transcriptional regulation. For example, when
rats are fasted for 48 h, hepatic Acsl1 and Acsl4 mRNA abundance increases, but Acsl3 and
Acsl5 mRNA abundance decreases [48]. When rats are refed a high sucrose diet, the reverse
occurs: hepatic Acsl1 and Acsl4 mRNA decreases, and Acsl5 mRNA abundance increases
[48]. These responses may reflect regulation by different transcription factors. PPARα, which
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is upregulated in liver during fasting, increases Acsl1 gene expression via a PPRE in the
Acsl1 promoter [49]. In contrast, the increase of hepatic ACSL5 mRNA by refeeding is
consistent with its upregulation by insulin via SREBP-1c [50]. Insulin also up-regulates
Acsl6 in heart [51]. Although the controls are, as yet, unknown, ACSLs are regulated differently
in different tissues. Thus, the fasting- induced changes in hepatic Acsl3 and Acsl5 mRNA levels
are not observed in adipose tissue or gastrocnemius muscle [48]. High-fat feeding greatly
increases Acsl1 mRNA in rat liver [6], but has no effect on Acsl1 mRNA in rat heart [51].
Treatment of rats with PPARγ agonists has no effect on Acsl1 mRNA in heart, but decreases
it in liver, and increases it 7-fold in epididymal and omental adipose tissue and 3-fold in skeletal
muscle [52]. These examples of tissue-specific regulation suggest that the ACSL isoforms each
contribute activated FAs that have different metabolic fates in each tissue.
In addition to transcriptional regulation with changes in mRNA abundance, the protein amounts
of individual ACSL isoforms, and total ACS activities are discordant under fasting and
refeeding condition and during development [48,53], suggesting that each isoform may be
regulated translationally or by post-translational modifications. The disconnect between
mRNA, protein and activity should be considered and further characterized in future studies.
Indirect evidence also suggests that ACS activity is regulated acutely. For example, in rat
adipocytes, norepinephrine and glucagon simultaneously decrease ACS activity and increase
lipolysis, whereas insulin rapidly reverses the norepinephrine effect and restores ACS activity
to control levels within 5 minutes [54]. The similar dose-response curves for ACS inactivation
and lipolysis stimulation [54], suggest that ACSL and hormone-sensitive lipase may be
regulated concomitantly in adipocytes. Since ACSL1 is the most abundant ACSL isoform in
adipocytes, and insulin does not alter the content of ACSL1 protein [55], the acute regulation
by insulin must occur via another mechanism. Perhaps during fasting, glucagon acutely inhibits
adipocyte ACSL1 by phosphorylation. Inactivating ACSL1 would prevent re-esterification of
newly hydrolyzed FA and would enhance the release of FA into the circulation. Rodent and
human ACSL1 contain two highly conserved serine residues that are predicted sites for protein
kinase A and Tyr-85 is phosphorylated in ACSL1 from rat liver [56].
Again arguing for independent regulation, ACSL isoforms are not only expressed in a tissue-
specific manner, but they are also expressed differently during development. During 3T3-L1
adipocyte differentiation, Acsl1 mRNA abundance increases ~160-fold while other isoforms
remain unchanged [23], suggesting that ACSL1 is the major isoform responsible for TAG
synthesis in adipocytes. In contrast, during the differentiation of PC12 neuronal cells, Acsl1
and Acsl3 mRNA content remains unchanged whereas that of Acsl4, 5, and 6 increases
significantly [23]. Further, in mouse heart, Acsl1 mRNA increases 4-fold postnatally, while
Acsl3 mRNA decreases and other ACSL isoforms do not change. These data suggest that
ACSL1 is the main isoform responsible for the 14-fold increase in ACS activity as the heart
adapts to the use of FA as its primary source of energy in the postnatal period [53]. In summary,
the unique developmental patterns of the ACSL isoforms suggest that they play different tissue-
specific roles during different stages of life.
Except for FATP1, the regulation of the FATP isoforms has been less well studied. Fatp1
mRNA increases 5- to 7-fold when 3T3-L1 cells differentiate into mature adipocytes [20]. In
mouse adipose tissue, fasting increases Fatp1 mRNA, suggesting a role that would be unrelated
to FA uptake or TAG synthesis [57]. Characterization of the FATP1 null mouse also suggests
that FATP1 is critical for acute insulin-stimulated uptake of exogenous FA [58].
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FAs and acyl-CoAs affect multiple cellular process that influence the etiology
of metabolic diseases
ACSL and FATP isoforms regulate the intracellular content of long-chain FA and acyl-CoA,
both of which are important intracellular signaling molecules. Long-chain acyl-CoAs have the
potential to alter multiple cellular processes including signal transduction via PKC isoforms
and Ca2+ release, enzymes involved in lipid and energy metabolism like acetyl-CoA
carboxylase and glucokinase [59], and ATP-sensitive K+ channels, including those that control
insulin release from pancreatic β-cells [60]. FAs and acyl-CoAs regulate numerous
transcription factors including the PPAR family, SREBP, ChREBP, LXR, HNF-4α and NF-
κβ [61].
Additionally, alterations in specific ACSL and FATP isoforms influence the concentration and
content of numerous intracellular lipids, many of which are intimately involved in disease
development. For example, apoptosis increases after pancreatic islets are incubated with FAs,
and is preceded by an 82% rise in ceramide; both apoptosis and the rise in ceramide can be
blocked by triacsin C, an inhibitor of ACSL isoforms 1, 3, and 4 [62]. On the other hand,
palmitate may induce apoptosis independent of ceramide production [63], perhaps related to
its inhibition of cardiolipin synthesis [64,65]. Palmitate-mediated apoptosis requires
metabolism, as evidenced by the finding that in β-cells, triacsin C blocked apoptosis as well
as the palmitate-mediated decrease in the anti-apoptosis factor Bcl-2, indicating that changes
in Bcl-2 requires acyl-CoAs or their metabolites [66]. Transgenic mice with overexpressed
ACSL1 in heart have increased TAG content in cardiac myocytes, cardiac hypertrophy, severe
left-ventricular dysfunction, and apoptosis of cardiac myocytes [17]. These studies exemplify
the importance role of the ACSL and FATP-isoforms in regulating fatty acid metabolism and
the subsequent metabolic changes that may lead to or prevent a host of metabolic diseases.
Acyl-CoA synthetases in pathological conditions
Increases or decreases in ACSL isoforms under pathological conditions suggest that each is
playing an independent role that cannot be compensated for by alterations in other isoforms.
For the most part, however, the effects of these alterations on tissue lipids or fatty acid
composition have not been investigated. ACSLs have been associated with various forms of
cancer, including acute myelogenous leukemia (ACSL6) [67], colorectal adenocarcinomas
(ACSL5) [68,69] and colon adenocarcinomas (ACSL4) [70]. It has been suggested that
upregulation of ACSL4, which has a marked preference for arachidonate [5], promotes
carcinogenesis by blocking the apoptosis that free arachidonate would otherwise induce [71].
ACS specific activity and Acsl1 mRNA abundance are upregulated in liver and adipose tissues
in genetic obese models such as Zucker fatty rat (fa/fa) and ob/ob mice [72,73]. Although the
causality between the change of ACSL isoforms and specific diseases has not been established,
these observations indicate that ACSL isoforms are linked to metabolic changes or FA demand
under several pathological conditions. For example, in patients with inflammatory bowel
disease, the increase of Acsl1 and Acsl4 mRNA in the terminal ileum and colon might provide
acyl-CoAs for the synthesis of phospholipids; these can serve as precursors for inflammatory
mediators or support membrane integrity of the affected intestine [74].
Despite the presence of other ACSL isoforms in brain, human ACSL4 is associated with
depression [75] and mutations in the human Acsl4 gene that decrease 20:4-CoA synthetase
activity cause a form of X-linked mental retardation [76–78]. The effect of these mutations
suggests that ACSL4 is critical for normal brain function, perhaps related to its preference for
long-chain polyunsaturated FAs [35], which are enriched in brain phospholipids.
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The differences in tissue expression, cellular location, enzyme kinetics and substrate
preferences suggest that individual ACSL, FATP, and ACSBG isoforms play unique roles in
FA channeling and lipid metabolism. In addition to controlling the metabolic fate of FAs, the
ACSL and FATP isoforms also regulate intracellular pools of FAs and acyl-CoAs, both of
which have broad effects on cellular metabolism ranging from altering gene expression to
allosterically regulating enzymes. Despite the importance of the ACS family in FA trafficking
and the intimate role of lipid metabolism in disease etiology, mechanisms linking the two have
been largely neglected.
Future perspectives
Although recent advances have provided insight into the physiological role of ACSLs, FATPs,
and ACSBGs, much work remains to elucidate their roles in FA channeling and the
development of disease. We anticipate that future studies will show that individual isoforms
of these enzymes differ in function depending on tissue-specific expression, expression of
splice variants, subcellular location, translational or post-translational modifications, and
expression of other proteins that interact with a given isoform. Because it is widely accepted
that the composition of FAs largely dictates their regulatory effects within the cell, identifying
the ACSL, FATP, and ACSBG isoforms that mediate specific effects of different FAs should
provide valuable insights. Additionally, identifying isoforms that influence the formation of
distinct pools of other intracellular lipids like DAG and ceramide may identify novel
pharmaceutical targets for diseases characterized by altered lipid metabolism and lipotoxicity.
Executive summary
Acyl-CoA synthetases in FA activation
• ACSL, FATP, and ACSBG activate long-chain and very-long-chain FA by a two-
step reaction
• ACSL, FATP, and ACSBG families include multiple isoforms that have distinct
enzyme kinetics, different but overlapping FA preferences, and unique subcellular
locations
The role of acyl-CoA synthetases in FA uptake
• ACSL and FATP isoforms are major regulators of both FA transport and metabolism
• ACSL and FATP isoforms located on intracellular membranes increase FA uptake,
suggesting that ACS activity and downstream metabolism enhance FA uptake and
that location on the plasma membrane is not required.
• ACSL and FATP appear to enhance FA uptake by activating FAs, a process that traps
FAs as acyl-CoAs within the cell and prevents efflux.
• Little is known about the specific role of the ACSBG isoforms.
The role of acyl-CoA synthetases in FA channeling
• In rat hepatoma cells, ACSL5 increases FA uptake and partitions it to TAG
• ACSL1 appears to be involved in TAG accumulation in adipose tissue, but, in liver,
it contributes to the synthesis of phospholipid and cholesterol. Thus, the functions of
individual isoforms may be tissue-specific
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• Similar to ACSL1, most studies support a role for FATP1 in TAG synthesis in adipose
tissue
• FATP4 is essential for normal skin development and its presence is required for
neonatal survival.
Differential regulation of acyl-CoA synthetases
• ACSL isoforms display tissue-specific response to nutritional changes. Potential
mechanisms include transcriptional, translational and post-translational regulations
• ACSL isoforms have different developmental patterns, suggesting specific roles
during adipocyte and heart development
• FATP1 expression responds to cell differentiation and nutritional changes
Acyl-CoA synthetases in pathological conditions
• Alterations in ACSL and FATP isoforms influence the content of intracellular lipids
• ACSL isoforms may be involved in certain cancers and in disorders like obesity,
diabetes and inflammatory bowel disease
• Mutations in the human Acsl4 gene cause a form of X-linked mental retardation
Unanswered questions
• What are the roles of splice variants of ACSL4 and ACSL6?
• Is ACSL1 inhibited in adipocytes during lipolysis to prevent reesterification and
promote FA efflux?
• How are FATPs regulated acutely, transcriptionally, and during development?
• Is channeling mediated by protein-protein interactions?
• What is the role of ACSBG in FA metabolism?
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Pathways initiated by ACSL, FATP, and ACSBG isoforms. In addition to initiating the
synthesis of triacylglycerol (TAG) and all the glycerophospholipids, acyl-CoAs are required
for the synthesis of cholesterol esters, ceramide and sphingolipids, for fatty acid (FA)
degradation pathways and for FA modification pathways of elongation and desaturation.
Intermediates in the glycerolipid synthetic pathway, lysophosphatidic acid (LPA),
phosphatidic acid (PA), and diacylglycerol (DAG) are intracellular signals. Both FA and acyl-
CoAs are also intracellular signals and regulators of cellular physiology as well as purported
ligands for PPAR and HNF4α transcription factors. G-3-P, glycerol-3-phosphate; PI,
phosphatidylinositol; PG, phosphatidylglycerol; CL, cardiolipin; PE
phosphatidylethanolamine; PC, phosphatidylcholine; PS, phosphatidylserine.
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